Search

Lynch syndrome - caused by pathogenic germline MLH1, MSH2, MSH2, PMS2, or EPCAM variants - is among the most common forms of inherited cancer susceptibility and predisposes to high risks of colorectal cancer, endometrial cancer, and other malignancies. We also eagerly await data from the CaPP3 trial of 1882 Lynch syndrome carriers, which will address the primary question about whether lower aspirin doses (100 mg/day and 300 mg/day) are non-inferior to 600 mg/day in reducing Lynch syndrome-associated colorectal cancer incidence. 378, 2011, 2081-2087 5 J Burn, H Sheth, F Elliott, Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. [Extracted from the article]

The authors discusses whether aspirin should be recommended for cancer prevention citing the results of the research study by Peter Rothwell and colleagues on the drug's potential to reduce the risk of cancer. The authors says that daily use of aspirin is linked with 21% reduction in the risk of cancer death based from the eight randomised trials analyzed by the researchers. They conclude that the study's data is another step closer to expanding recommendations for the use of aspirin.

This article presents an opinion on studies that are suggesting a daily regime of aspirin may prevent colorectal cancer. The studies showed that aspirin reduces the recurrence of colorectal adenomas in high-risk individuals with a history of adenoma or cancer, but since most adenomas do not progress to cancer, it is uncertain if aspirin will translate into a meaningful reduction of risk for the disease.